Pursuant to Regulation 47(3) of SEBI (LODR) Regulations,2015 we have published our Audited Financial Results as on 31-03-2025 which was approved in the Board Meeting held on 16-5-2025 in ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd has filed audited financial results for the quarter and year ended 31 March 2025, approved by the Board on 16 May 2025 and published in Free Press Journal and Navshakti on 17 May 2025 under SEBI LODR Regulation 47(3). Revenue from operations stood at Rs. 152.70 lakhs in Q4 FY25 versus Rs. 173.64 lakhs in Q4 FY24, while full-year FY25 revenue was Rs. 682.56 lakhs versus Rs. 730.46 lakhs in FY24. The company swung to a net loss of Rs. 9.66 lakhs in FY25 compared to a profit of Rs. 48.67 lakhs in FY24, with Q4 FY25 also posting a loss of Rs. 9.66 lakhs versus a profit of Rs. 13.60 lakhs a year ago. Basic and diluted EPS for FY25 came in at Rs. 0.54, down from Rs. 0.60 in FY24. The results were audited and carry an unqualified opinion from the statutory auditors.
A clear decline in revenue and a swing from profit to loss for the full year signals weak operating performance, which is negative for shareholders and likely to weigh on the stock in the near term.